e-learning
resources
London 2016
Sunday, 04.09.2016
IPF: from pathogenesis to treatment I
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Marlies S. Wijsenbeek (Rotterdam, Netherlands), Marlies S. Wijsenbeek-Lourens, Merel L. Kimman, Adrienne Rotteveel, Xana van Jaarsveld, Stephanie S. Weinreich, Remy Mostard, Carmen D. Dirksen
Source:
International Congress 2016 – IPF: from pathogenesis to treatment I
Session:
IPF: from pathogenesis to treatment I
Session type:
Thematic Poster
Number:
793
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Marlies S. Wijsenbeek (Rotterdam, Netherlands), Marlies S. Wijsenbeek-Lourens, Merel L. Kimman, Adrienne Rotteveel, Xana van Jaarsveld, Stephanie S. Weinreich, Remy Mostard, Carmen D. Dirksen. The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF). Eur Respir J 2016; 48: Suppl. 60, 793
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Quality of life of patients with idiopathic pulmonary fibrosis (IPF) - What can the Australian IPF registry tell us?
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Development of a national patient charter for idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Predicting life expectancy for pirfenidone and best supportive care (BSC) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Patients’ expectations and quality of life before introduction of pirfenidone used in idiopathic pulmonary fibrosis.
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
The lived experience of idiopatic pulmonary fibrosis: A qualitative study
Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences
Year: 2016
Quality of life measures in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
The efficacy of a walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis (IPF). A pilot study
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Quality of life in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 30s
Year: 2005
Quality of life of idiopathic pulmonary fibrosis patients
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Health status & impact of living with idiopathic pulmonary fibrosis (IPF): UK & Ireland Delphi survey
Source: International Congress 2016 – IPF clinical
Year: 2016
Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020
Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
Source: Breathe, 15 (2) 144; 10.1183/20734735.0016-2019
Year: 2019
The physical and psychological needs of patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
A longitudinal study of anxiety and depression in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept